Company ProfilePremium

Amcil Limited

Company Profile Analysis

Ticker: AMH.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Amcil Limited - Company showcase

Year Founded & Workforce

1996

Amcil Limited logo

Amcil Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Amcil Limited Overview

AMCIL Limited is a small, internally administered Australian listed investment company that runs a deliberately concentrated, benchmark-unaware portfolio of roughly 30–45 high-quality Australian and New Zealand listed companies, spanning mega-caps such as Macquarie Group, BHP and CSL alongside founder-led small and mid-caps such as ARB Corporation, Netwealth and Temple & Webster. It sits within the AFIC family of four LICs serviced at cost by Australian Investment Company Services, which gives it institutional research depth and a sub-0.6% management expense ratio with no performance fees despite a portfolio of only ~A$340 million. Its stated objectives are medium-to-long-term capital growth and fully franked dividends, supplemented by special dividends funded from realised gains. AMCIL's distinctive feature — equal emphasis on small and large companies in a focused book — produced strong outperformance in FY2024 but severe underperformance in FY2025–FY2026, leaving the shares at a persistent mid-teens discount to NTA as a new CEO takes charge.


What the company does

AMCIL is a closed-end listed investment company. It raises permanent equity capital from shareholders, invests that capital in listed equities, and returns value to shareholders through (i) growth in net asset backing per share and (ii) fully franked dividends funded from the dividend income it receives plus, periodically, realised capital gains. Because it is closed-ended, it is never forced to sell assets to meet redemptions, which is the core structural advantage LIC managers emphasise over open-ended managed funds.

Company's own description (paraphrased from AR FY2026). AMCIL describes itself as managing a focused portfolio covering large and small companies in the Australian and New Zealand equity markets. Its investment objectives are attractive returns through strong capital growth in the portfolio over the medium to long term, together with the generation of fully franked dividends. The investment philosophy centres on "quality first", followed by growth and value: it prefers companies with leadership positions in their industries and durable competitive advantages, long-term sustainable business models with low disruption risk, limited exposure to adverse regulatory influences, outstanding management and boards aligned with shareholders, stable income flows and strong, self-funding balance sheets. It evaluates metrics such as return on capital employed, return on equity, gearing, margins and free cash flow, and it votes on every resolution at investee companies, publishing its voting record.

Independent characterisation. AMCIL is best understood as a high-conviction, quality-growth Australian equity strategy wrapped in a tax-efficient corporate structure. Relative to its larger sibling AFIC (a diversified, income-oriented, ~A$9.8 billion portfolio), AMCIL is the group's "concentrated, all-cap" vehicle: its top 20 holdings were 72.6% of the portfolio at 30 June 2026, and small companies are permitted to carry position sizes that matter. The strategy has historically leaned heavily toward healthcare, technology and "owner-driver" businesses and away from banks and resources, which made it highly sensitive to the FY2026 market rotation into Materials (+52.1%) and out of Healthcare (−36.2%) and Information Technology (−37.0%), as reported in AR FY2026.

Business model and revenue model

Revenue / value streamNatureFY2026 amount (AUD K)Share of income from operating activitiesSource
Dividends and distributions from portfolio companiesRecurring investment income; largely franked8,45286.2%AR FY2026 Income Statement
Interest on cash deposits (Commonwealth Bank)Recurring, rate-sensitive8188.3%AR FY2026
Income from options written portfolioCall options written over holdings; opportunistic premium income5305.4%AR FY2026
Net gains on trading portfolioSmall short-term trading book; nil in FY202600.0%AR FY2026
Income from operating activities—9,800100%AR FY2026
Realised capital gains (pre-tax, through OCI, not profit)Funds special dividends and "LIC capital gain" attributable amounts8,780n/a (capital account)AR FY2026 Statement of Comprehensive Income

There is no product, service, subscription or licensing revenue. The "revenue mix" of an LIC is a mix of investment income types. Shareholder value creation is dominated by the capital account (FY2026 unrealised losses of A$59.6 million pre-tax dwarfed operating profit of A$6.9 million), so reported "profit" is a poor guide to economic performance; the relevant measure is total portfolio return (net asset growth plus dividends including franking), which was −10.0% in FY2026.

Value-chain position, customers and end-markets

Value-chain position: Capital allocator / end-investor in listed equities. AMCIL sits downstream of the stock exchange and upstream of retail shareholders; it does not intermediate client money in the way an asset manager does.

Customer types (shareholders): Predominantly Australian retail investors, self-managed super funds (SMSFs), family offices and private foundations. At 20 July 2026 there were 2,864 holdings; the 20 largest holders owned 35.19% and the Teele family entities collectively held ~17% (AR FY2026). Holdings of 100,000+ shares accounted for 81.95% of capital.

End-markets (where capital is deployed): Australian and New Zealand listed equities across Healthcare (15.6% of portfolio), Other Financials & Real Estate (22.2%), Industrials (14.6%), Information Technology (10.4%), Telecommunications/Communication Services (9.3%), Materials (8.6%), Consumer Discretionary (7.2%), Consumer Staples (3.6%), Energy (3.4%), Banks (0.0%) and Cash (5.0%) at 30 June 2026 (AR FY2026 Note B3).

Cost model: AMCIL pays AICS an administration fee (A$1.181 million in FY2026) covering investment management, financial reporting and key personnel, plus its own "other administration expenses" (A$0.930 million, of which directors' fees were A$0.435 million). There is no base management fee linked to funds under management in the conventional external-manager sense and no performance fee (FNN interview, FY2025 results).

Strategy

Stated strategy (themes from AR FY2026 and FY2026 results webcast)

  1. Quality first, then growth, then value. Six quality criteria (industry leadership, sustainable low-disruption model, regulatory resilience, aligned management and governance, stable income, financial strength) remain unchanged from AR FY2024 to AR FY2026.

  2. Focused, high-conviction portfolio of 30–40 companies, large and small. The FY2026 webcast reiterated a high-conviction book of 30 to 40 high-quality companies. Late in FY2026 management actively reduced the number of holdings to concentrate capital where long-term conviction is highest relative to risk.

  3. Long-term, tax-aware ownership with low turnover — although turnover rose to ~27% in FY2026 during the restructuring.

  4. Fully franked dividends supplemented by specials from realised gains, with LIC capital gain attributable amounts passed through to shareholders.

  5. Low cost, internally administered model — no performance fees; MER 0.57%.

  6. Discount management — enhanced broker and financial-planner communication, weekly NTA disclosure and orderly on-market buy-backs.

  7. Responsible ownership — voting on all resolutions, engagement on governance, consideration of climate and social risks; portfolio carbon intensity assessed (using ISS ESG data) as below the S&P/ASX 200.

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailTarget / metricSource
Bank exit programmeFY2025–FY2026Exited CBA (FY2025), then Westpac and NAB (FY2026); banks 0% of portfolioValuation disciplineAR FY2026; FNN FY2025
Technology de-riskingFY2026Exited REA Group and WiseTech Global; reduced IT from 15.3% to 10.4%Reduce concentration and AI-disruption riskAR FY2026
Small-cap pruningFY2026Exited EQT Holdings, ReadyTech, Beamtree, Redox, The Environmental Group, IDP EducationHigher convictionAR FY2026
Contrarian turnaround additionsFY2026Initiated Ramsay Health Care, ASX Ltd (new management), AUB Group (de-rated), Nanosonics; added to SEEK, Sigma, WoodsideValue entry into quality franchisesAR FY2026
On-market buy-backFY2025–FY2026 (plan announced 22 Jan 2026)3.9m shares (A$4.3m) in FY2025; 7.5m shares (A$7.6m, avg A$1.01) in FY2026Accretive at ~16% discountAR FY2026
Weekly NTA disclosureFY2026Estimated pre-tax NTA released weeklyDiscount narrowingAR FY2026
Mandate broadening languageFY2025Description changed to "Australian and New Zealand" equity markets—AR FY2025/FY2026
CEO successionFeb–Jul 2026Gibson succeeds Freeman across all four AICS LICsLeadership continuityAFIC announcement 17 Feb 2026
Cash reserve for dislocationsFY2026Cash ~5% of portfolio retained for market dislocationsOpportunistic deploymentAR FY2026 Outlook

Guidance and medium-term targets

AMCIL does not provide earnings guidance or medium-term financial targets; the Directors state explicitly that they do not believe it possible or appropriate to forecast markets or investment results (AR FY2026, Likely Developments). Implicit benchmarks are the S&P/ASX 200 Accumulation Index (including franking) over 1/3/5/10 years and the MER trend. No cost programme with a quantified target has been announced.

Products & Services

Products offered to investors

"Product" / serviceDescriptionTarget customerPricing / termsSource
AMH ordinary sharesSingle class of fully paid ordinary shares; one vote per share on a pollRetail, SMSF, family officesMarket price on ASX; currently at ~16% discount to pre-tax NTAAR FY2026
Dividend Reinvestment Plan (DRP)Dividends reinvested in new shares priced at the 5-day average selling price after ex-date; no discountExisting holders0% discount (FY2026 dividend notice)AR FY2026 Note D6; dividend notice 28 Jul 2026
Dividend Substitution Share Plan (DSSP)Holders forgo the dividend and receive shares instead (tax-deferral feature)Higher-tax-rate holdersPriced as per DRPAR FY2026 Note D6
LIC capital gain attributable partTax-deduction entitlement attached to dividends paid from realised long-term gains; 2.14c per share attached to FY2026 final + specialEligible taxpayersEmbedded in dividendAR FY2026
Weekly estimated NTA and monthly NTA/top-20 reportsTransparency tools introduced/expanded partly to address the discountAll investorsFree (ASX releases, website)AR FY2026 Share Price section
Shareholder webcasts and AGM (hybrid)Half-year and full-year results webcasts; hybrid AGMsAll investorsFreeFY2026 Appendix 4E

Investment portfolio — complete holdings register at 30 June 2026 (the operating "catalog")

CodeCompanyActivity (summarised)Shares held FY2025 (000)Shares held FY2026 (000)Market value FY2026 (AUD K)% of portfolio
MQGMacquarie GroupDiversified financial services1039624,1037.5
BHPBHPDiversified resources44238222,6827.0
TCLTransurban GroupToll roads1,2261,22617,6305.5
GMGGoodman GroupIndustrial property54644613,8844.3
MFTMainfreight (NZX)Freight and logistics24924912,6873.9
CSLCSLBiopharmaceuticals12111012,6443.9
WOWWoolworths GroupSupermarkets22830812,3293.8
CARCAR GroupOnline auto classifieds39745311,6693.6
WDSWoodside EnergyOil and gas23041211,6233.6
RMDResMedSleep/respiratory devices33734710,0073.1
SIGSigma HealthcarePharmacy (Chemist Warehouse)2,0543,5249,6913.0
TLSTelstra GroupTelecommunications1,5381,8809,5503.0
MAQMacquarie Technology GroupData centres, telco2001349,3912.9
RHCRamsay Health CarePrivate hospitals01958,5542.7
ALQALSTesting laboratories5503658,3372.6
WESWesfarmersDiversified retail/industrial123918,2352.6
XYZBlock IncFintech / payments56728,2352.6
ARBARB Corporation4WD accessories3844037,6232.4
RGNRegion GroupShopping centre REIT3,2503,2507,5732.3
AIAAuckland International AirportAirport7801,0757,4892.3
FPHFisher & Paykel HealthcareRespiratory devices2302307,3722.3
NWLNetwealth GroupInvestment platform3433296,7642.1
AUBAUB GroupInsurance broking02296,5682.0
NXTNEXTDCData centres3094406,4202.0
TNETechnology OneEnterprise software1682146,3082.0
ASXASX LtdSecurities exchange01075,6791.8
BRGBreville GroupSmall appliances1411695,4491.7
SEKSEEKEmployment classifieds653985,3531.7
EVTEVTCinemas, hotels3103915,0301.6
OCLObjective CorpGovernment software3484334,4651.4
360Life360Family location app1371413,7541.2
JHXJames Hardie IndustriesFibre cement246943,5861.1
REHReecePlumbing distribution2401963,3771.0
TPWTemple & WebsterOnline furniture2204923,0520.9
COHCochlearHearing implants24242,8850.9
AMCAmcorPackaging526462,8780.9
XROXeroCloud accounting27392,8060.9
GTKGentrack GroupUtility billing software7156872,1700.7
NANNanosonicsInfection control05701,8980.6
HUBHUB24Investment platform42221,6140.5
PXAPEXA GroupDigital property settlement01001,0300.3
—Total———322,394100.0

All 41 listed holdings disclosed in AR FY2026 "Holdings of Securities", with 2025 and 2026 share counts and 2026 market values.

Notes: (1) AMCIL also holds an unlisted Level 3 investment in Marketplacer (software), disclosed in Note A2; it carried A$487k in AR FY2024 and does not appear as a separate line in the FY2026 holdings table, implying an immaterial or nil carrying value (not separately disclosed). (2) PEXA's FY2025 count is shown as zero in AR FY2026 although AMCIL held 209k shares at 30 June 2024; this implies an exit in FY2025 and re-entry in FY2026.

Top-20 concentration trend

Concentration metricFY2024FY2025FY2026
Top 20 as % of portfolio (excl. cash)74.8—72.6
Largest single holding %9.17.47.5
Number of holdings over 5%423
Number of listed holdings at 30 June44—41

Sources: AR FY2024; AR FY2026. FY2024 largest holding was CSL (9.1%); FY2025 CSL (7.4%); FY2026 Macquarie Group (7.5%).

Financial Narrative

Basis. FY2023–FY2026 statutory figures are from AR FY2024 and AR FY2026 (which contain FY2023 and FY2025 comparatives). FY2022 figures come from the 5-Year Summary in AR FY2026, the opening balances in AR FY2024's Statement of Changes in Equity and Cash Flow Statement, and — where flagged — the aggregator Stoxray (FY2022 operating income A$9.306m and operating cash flow A$6.321m). For an LIC with no depreciation or amortisation, "operating income" is defined here as profit before finance costs and tax, and EBITDA equals operating income. "Revenue" is "income from operating activities".

Income statement (A$000 unless stated)

Gross profit is not a meaningful concept for an LIC (there is no cost of goods sold); gross margin is therefore not presented. Diluted EPS equals basic EPS because there are no options or convertibles on issue (AR FY2026 Note A5). FY2022 EPS is the rounded 5-Year Summary figure. FY2022 MER (0.52%) is from the AR FY2023 "Year in Summary" comparative.

Margins and growth (%)

CAGRs (FY2022→FY2026, four years): income from operating activities +1.3% p.a. (A$9.306m → A$9.800m, FY2022 aggregator base); NPAT −3.9% p.a. (A$8.115m → A$6.920m); pre-tax NTA per share +1.2% p.a. (A$1.03 → A$1.08); ordinary dividend flat at 3.5c. The low effective tax rate reflects franking-credit offsets on franked dividends received (A$1.37m offset in FY2026, Note B2).

Commentary. Profit has trended down since the FY2022 peak because AMCIL has steadily rotated away from high-yield stocks (banks, BHP, Wesfarmers) toward lower-yielding growth and quality names, and because the portfolio itself shrank in FY2026. FY2026 bucked the trend modestly (+3.6%) thanks to higher interest income (A$818k vs A$537k), a recovery in options premium (A$530k vs A$357k) and a 9% cut in administration costs (A$2.111m vs A$2.314m), principally lower AICS fees. Margins are structurally high and stable (70–80%) because the cost base is small and largely fixed; the FY2025 dip reflects a one-year rise in AICS fees.

Balance sheet (A$000 at 30 June)

FY2022 cash, equity, reserves and share count are the 1 July 2022 opening balances in AR FY2024; FY2022 investments and NTA from the 5-Year Summary (AR FY2026). AMCIL has a A$10 million cash advance facility with Commonwealth Bank, undrawn at every year-end reviewed and now expiring 30 June 2028 (AR FY2026 Note D2); AR FY2024 notes the facility was utilised intra-year in FY2024.

Commentary. The balance sheet is ungeared and highly liquid: 95% of assets are Level 1 listed equities and the remainder is cash. Equity fell A$49.8 million in FY2026 (−13.7%) through a combination of A$35.8 million of net-of-tax investment losses, A$20.2 million of dividends paid (inflated by the 3.0c FY2025 special) and A$0.7 million net capital reduction (A$7.6 million buy-backs exceeding A$7.0 million of DRP issuance). The deferred tax liability on unrealised gains roughly halved to A$25.4 million, which is why the gap between pre- and post-tax NTA narrowed from 14c to 9c. The realised capital gains reserve (A$25.0 million) and the LIC capital gain account (A$7.6 million attributable gain, of which A$6.7 million is being distributed with the FY2026 final and special dividends) are the reservoirs for future special dividends.

Cash flow (A$000)

Commentary. Operating cash flow covers the ordinary dividend (3.5c × ~315m shares ≈ A$11 million) only about 0.6×; the gap is closed by realised gains, DRP reinvestment and the run-down of retained profits. This is normal for a total-return LIC that pays a "profit + realised gains" distribution, but it means ordinary dividend sustainability depends on the portfolio continuing to generate both franked income and taxable gains. Portfolio turnover (sales ÷ average portfolio) rose from roughly 15% in FY2023 to 18% in FY2024, 20% in FY2025 and 27% in FY2026, a notable increase for a self-described "low turnover, tax-aware" investor and a sign of the late-FY2026 portfolio restructuring. Brokerage paid rose to A$474k in FY2026 (416 transactions) from A$325k in FY2024 (354 transactions).

Ratios

Cash conversion cycle: not applicable (no inventories, trade receivables are settlement-cycle only, no trade payables of substance).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Portfolio Details

PortfolioPurposeAccounting treatmentSize at 30 Jun 2026

Investment portfolio

Long-term holdings

Fair value through other comprehensive income (OCI); gains/losses never recycled to profit

A$322.4 million

Options written portfolio

Call (and occasionally put) options written over investment holdings to earn premium

Fair value through profit or loss

Nil open at 30 June 2026 (A$73k liability at 30 June 2025)

Trading portfolio

Small short-term positions

Fair value through profit or loss

Nil

Income stream (AUD K)

Income stream (AUD K)FY2023FY2024FY2025FY2026

Dividends and distributions

9,3719,2318,6028,452

Interest on deposits

401293537818

Other income

0500

Net gains on trading portfolio

-6209860

Income from options written portfolio

578391357530

Income from operating activities (total)

10,34410,1299,5829,800

Revenue by Segment (%) and Segment Margins & Growth (%)

Derived metric (%)FY2023FY2024FY2025FY2026

Dividends as % of operating income

90.691.189.886.2

Interest as % of operating income

3.92.95.68.3

Options + trading as % of operating income

5.56.04.65.4

YoY growth in operating income

—-2.1-5.42.3

Pre-tax profit margin on operating income

77.478.574.977.5

Revenue by Segment (%)

Sector (%)FY2023FY2024FY2025FY2026

Energy

2.551.521.323.43

Materials

9.627.838.278.59

Industrials

14.7514.3613.6614.60

Consumer Discretionary

12.3813.008.127.18

Consumer Staples

3.141.941.733.63

Banks

8.097.082.950.00

Other Financials and Real Estate

16.9218.1219.3922.23

Telecommunications

12.007.869.149.31

Healthcare

16.0614.7615.7815.64

Information Technology

3.0510.5315.2510.41

Cash

1.443.004.394.98

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Income from operating activities (AUD K; FY2022 aggregator)

9,30610,34410,1299,5829,800

Total revenue — dividends, interest, other (AUD K)

—9,7729,5299,1399,270

Administration expenses (AUD K)

—2,2422,0612,3142,111

of which AICS administration fee (AUD K)

—1,2161,0111,3431,181

Operating income = EBITDA (AUD K)

—8,1028,0687,2687,689

Finance costs (AUD K)

—911139092

Profit before tax (AUD K)

—8,0117,9557,1787,597

Income tax expense (AUD K)

—456477499677

Net profit after tax (AUD K)

8,1157,5557,4786,6796,920

Basic EPS (A$ cents)

2.72.432.382.112.19

Diluted EPS (A$ cents)

2.72.432.382.112.19

Dividends declared per share (A$ cents, incl. special)

3.55.04.06.54.0

of which special dividend (A$ cents)

01.50.53.00.5

Total comprehensive income (AUD K)

—27,93747,16120,011-28,891

Management expense ratio (%)

0.520.660.560.560.57

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

EBITDA / operating margin (%)

—78.379.775.978.5

Pre-tax margin (%)

—77.478.574.977.5

Net margin (%)

87.273.073.869.770.6

Effective tax rate (%)

—5.76.07.08.9

Operating income growth YoY (%)

—11.2-2.1-5.42.3

NPAT growth YoY (%)

—-6.9-1.0-10.73.6

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Cash and equivalents (AUD K)

21,7144,95411,94618,04216,890

Investment portfolio at market value (AUD K)

306,600341,359386,196392,695322,394

Total assets (AUD K)

—348,485399,498412,018340,617

Total debt — short term (AUD K)

00000

Total debt — long term (AUD K)

00000

Net debt (negative = net cash) (AUD K)

-21,714-4,954-11,946-18,042-16,890

Deferred tax liability on investment portfolio (AUD K)

17,86027,59743,22943,09325,382

Total liabilities (AUD K)

—28,28444,26749,39127,809

Shareholders' equity (AUD K)

300,970320,201355,231362,627312,808

Share capital (AUD K)

221,801223,819227,101226,910226,204

Revaluation reserve (AUD K)

27,33748,18182,38582,00740,100

Realised capital gains reserve (AUD K)

37,26626,08019,24032,95025,038

Retained profits (AUD K)

14,56622,12126,50520,76021,466

Goodwill and intangibles (AUD K)

00000

Working capital (AUD K)

—5,65312,36613,11615,895

Shares on issue (millions)

309.9311.9315.4315.4314.5

NTA per share pre-tax (AUD)

1.031.121.261.291.08

NTA per share post-tax (AUD)

—1.031.131.150.99

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (AUD K; FY2022 aggregator)

6,3217,6607,0366,4746,326

Capital expenditure (AUD K)

00000

Free cash flow (AUD K)

6,3217,6607,0366,4746,326

Sales from investment portfolio (AUD K)

—47,79666,79976,21696,817

Purchases for investment portfolio (AUD K)

—53,30254,71263,28177,258

Tax paid on capital gains (AUD K)

—10,20806986,109

Dividends paid (AUD K)

—10,72415,41312,42420,222

Shares issued under DRP (AUD K)

—2,0293,2994,1476,961

Share buy-backs (AUD K)

—004,3057,616

Net change in cash (AUD K)

—-16,7606,9926,096-1,152

Dividends paid / operating cash flow (%)

—140219192320

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE — NPAT / closing equity (%)

2.702.362.111.842.21

Comprehensive ROE — total comprehensive income / closing equity (%)

—8.7213.285.52-9.24

ROA — NPAT / closing total assets (%)

—2.171.871.622.03

ROIC — operating income / (equity + debt − cash) (%)

—2.572.352.102.59

Current ratio (x)

—9.2314.213.117.83

Debt / equity (x)

00000

Net debt / EBITDA (x)

—-0.61-1.48-2.48-2.20

Interest coverage — EBIT / finance costs (x)

—89.071.480.883.6

Asset turnover — operating income / total assets (%)

—2.972.542.332.88

Dividend payout — DPS declared / EPS (%)

130206168308183

Portfolio turnover — sales / average portfolio (%)

—14.818.419.627.1

Revenue by Region

Exposure by issuer domicile (AUD K)FY2024FY2026

New Zealand-domiciled (Mainfreight, Auckland Airport, Fisher & Paykel, Gentrack, Xero)

37,91332,524

Offshore-domiciled, ASX-listed (ResMed, Block, Life360, James Hardie)

22,20925,582

Australian-domiciled

325,913264,288

Total investment portfolio

386,035322,394

Exposure share (%)

Exposure share (%)FY2024FY2026

New Zealand-domiciled

9.810.1

Offshore-domiciled, ASX-listed

5.87.9

Australian-domiciled

84.482.0

Capital Markets Data and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Share price at 30 June (A$; FY2023–FY2025 implied from NTA and discount)

—1.011.101.080.90

Pre-tax NTA per share (AUD)

1.031.121.261.291.08

Discount to pre-tax NTA (%)

—10.013.016.416.3

Market capitalisation at 30 June (AUD Mn; FY2023–FY2025 InvestSMART)

—313.4346.9339.1283.1

Portfolio return incl. franking (%; FY2023 per AR FY2023 summary)

—13.520.56.4-10.0

S&P/ASX 200 Accumulation incl. franking (%)

——13.515.17.2

Total shareholder return incl. franking (%)

—-2.117.5——

Number of shareholders

3,3503,2413,1653,0662,876

Share Price & Returns

HorizonPortfolio return incl. franking (% p.a.)Index incl. franking (% p.a.)Share price (price only)

1 year

-10.07.2

−16.3% (A$1.075 → A$0.90); TSR ≈ −10.2% before franking including 6.5c paid

3 years

4.911.9

−10.5% cumulative (A$1.005 → A$0.90); TSR ≈ +5.0% cumulative before franking including 15.5c paid

5 years

2.39.2—

10 years

7.810.9—

Valuation Multiples

MultipleAMCILBasis

P/E (trailing)

41.1x

EPS 2.19c

Price / pre-tax NTA

0.83x

NTA A$1.08

Price / post-tax NTA

0.91x

NTA A$0.99

P/B (statutory book)

0.91x

Equity A$312.8m ÷ 314.5m shares = A$0.995

EV / EBITDA

34.6x

EV = A$283.1m − A$16.9m cash = A$266.2m; EBITDA A$7.69m

EV / Sales

27.2x

Operating income A$9.80m

Dividend yield (FY2026 declared 4.0c)

4.4% net; 6.3% grossed up

At A$0.90

Ordinary dividend yield (3.5c)

3.9% net; 5.6% grossed up

At A$0.90

Dividend (A$ cents per share)

Dividend (A$ cents per share)FY2022FY2023FY2024FY2025FY2026

Interim

1.01.01.01.01.0

Final

2.52.52.52.52.5

Special

01.50.53.00.5

Total

3.55.04.06.54.0

LIC capital gain attributable amount on final/special

3.575.7106.432.14

Franking (%)

100100100100100

Analyst Conclusions

Management outlook

Management (AR FY2026, July 2026) views the Australian market as moderately expensive against long-term averages, expects sector valuation dispersion to drive volatility through the August 2026 reporting season, believes the portfolio's strong-balance-sheet holdings are positioned for earnings growth, and retains a healthy cash level for dislocations. No quantitative guidance is provided. Post-balance-date, pre-tax NTA recovered from A$1.04 (24 July) to A$1.09 ex-dividend at 31 August 2026.

Consensus

No sell-side consensus exists. Implied market expectations — embodied in a ~16–17% discount — are for continued relative underperformance or persistent structural discount.

Bull case

  1. Discount capture plus buy-back accretion. At ~A$0.90 against ~A$1.09 NTA, investors buy the portfolio at ~83c in the dollar; the company itself repurchased 2.4% of capital in FY2026 at an average A$1.01, and continued buying at sub-A$0.95 is materially accretive.

  2. Style mean reversion. The FY2026 loss was driven by sector rotation (Healthcare −36.2%, IT −37.0%) rather than balance-sheet failure; AMCIL has re-entered de-rated franchises (Ramsay, ASX, AUB, SEEK) at what management describes as attractive valuations, echoing the FY2024 rebound (+20.5%).

  3. New leadership catalyst. A new CEO with a decade inside the AICS investment team and external HESTA experience can reset portfolio construction and discount-management policy without disrupting a 90-year group process.

Bear case

  1. Track record erosion. AMCIL now lags its benchmark over 1, 3, 5 and 10 years (10-year 7.8% vs 10.9% p.a.), undermining the central rationale for a higher-cost concentrated vehicle.

  2. Structural sub-scale. At ~A$340m, the MER (0.57%) is roughly four times that of AFIC and Argo, and the shrinking register (−14% holders since FY2022) suggests the discount may be structural rather than cyclical.

  3. Income and dividend pressure. Dividend income has fallen three years running; EPS (2.19c) does not cover the 3.5c ordinary dividend, and the LIC gain account was largely distributed with the FY2026 final/special, limiting future specials unless gains are realised.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Weekly / monthlyEstimated NTA and discount trajectory; buy-back execution volumes
Oct 2026 onwardAny strategy statements from the new CEO following the 1 Oct 2026 AGM; AGM vote outcomes
Jan 2027 (scheduled 21 Jan 2027 per aggregators)H1 FY2027 results: half-year return vs index, interim dividend, MER
OngoingRecovery of healthcare holdings (CSL, ResMed, Cochlear, Ramsay) and IT/classifieds (CAR, SEEK, TechnologyOne, Netwealth)
OngoingAny discount-control mechanisms (e.g., expanded buy-back, conditional tender offer, merger with a sister LIC) — none announced; speculative
OngoingTax policy changes affecting franking or CGT for LIC shareholders
Jul 2027FY2027 results; whether special dividends continue

Concluding analyst verdict

AMCIL is a well-governed, ungeared, low-cost (for its size) listed investment company whose investment process is sound but whose recent outcomes have been poor. The FY2026 result crystallises the tension: accounting profit rose 3.6% to A$6.9 million and administration costs fell 9%, yet the portfolio lost 10.0% against a 7.2% gain for the index, net assets fell 14%, and the shares remained stuck at a 16% discount to NTA. The underperformance was overwhelmingly a style event — a heavy healthcare and technology overweight and zero bank exposure colliding with a resources-led market and an AI-driven de-rating of software and classifieds — rather than evidence of capital impairment, and the portfolio's quality characteristics (strong balance sheets, leadership franchises) remain intact.

The investment case now rests on three variables. First, whether the concentrated quality-growth style recovers; AMCIL's FY2024 experience shows how quickly relative returns can swing when the regime turns. Second, whether the new CEO, Alison Gibson, treats the discount as a strategic problem rather than an uncontrollable market outcome; buy-backs at ~83c in the dollar are clearly accretive, but more decisive capital-management options exist within a four-LIC group sharing one manager. Third, whether the vehicle can justify its scale: a A$340 million portfolio with a 0.57% MER competing against sister vehicles at 0.14% is structurally challenged.

On balance, AMCIL screens as a deep-value, catalyst-dependent holding: the 17% discount and fully franked yield (~6.3% grossed up on FY2026 declarations) provide some margin of safety, but persistent long-horizon underperformance and sub-scale economics mean the discount may not close without either a performance turnaround or a corporate initiative. Monitoring priorities are the NTA discount, buy-back intensity, the first half under new leadership, and any strategic review of the group's LIC structure.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedCommitteesBackground (summarised)EducationShares held 30 Jun 2026

Rupert Myer AO

Chairman, independent NED

Jan 2000 (Chair 2020)

Chair, Investment Committee

President, The Myer Foundation; Chairman, Yulgilbar Group; former Deputy Chairman Myer Holdings; former director Diversified United Investments, Healthscope

BCom (Hons) Melb, MA Cantab, FAICD

2,424,016

Alison Gibson

Managing Director & CEO (from 13 Jul 2026); also MD of AICS, AFIC, DJW, MIR

Jul 2026

Investment Committee

Portfolio Manager, Internal Australian Equities, HESTA; Portfolio Manager at the AICS LICs 2011–2021; earlier Executive Director, Goldman Sachs JBWere; 25+ years' experience

CFA, B Bus, Grad Dip App Fin, GAICD

Nil direct at 13 Jul 2026 (initial notice)

Roger Brown

Independent NED

Feb 2014

Investment Committee

NED of ARB Corporation; ARB Executive Chairman 1987–2016 and NE Chairman 2016–2022

B.Eng, MBA

2,260,015

Paula Dwyer

Independent NED

Jun 2023

Audit and Investment Committees

Chair, Allianz Australia; NED TPG Telecom; former Chair Tabcorp, Healthscope, Blackmores; former NED ANZ (Audit Chair), Suncorp, Dexus Funds Management

BCom, FCA, SF Fin, FAICD

110,868

Michael (Mike) Hirst

Independent NED

Jan 2019

Chair, Audit Committee; Investment Committee

Chairman, AMP Limited; Director, Adelaide Airport, GMHBA; CEO Bendigo and Adelaide Bank 2009–2018

B Com (Melb), SF Fin, FAICD

284,304

Jon Webster AM

Independent NED

Nov 2016

Audit and Investment Committees

Former Allens M&A partner (30+ years) and Allens board member; trustee R E Ross Trust; former member ASIC Audit and Risk Committee

BCom, LLB (Hons), LLM

3,600,260

Mark Freeman

Managing Director (retired 30 Jun 2026)

CIO Feb 2007; CEO/MD Jan 2018

Investment Committee

Former Partner, Goldman Sachs JBWere (12 years advising the LICs)

BE, MBA, Grad Dip App Fin, AMP (INSEAD), GAICD

1,300,577 (at retirement)

Executive Leadership Team

NameTitleJoinedPrior roles

Alison Gibson

MD & CEO

Jul 2026

HESTA; AICS 2011–2021; Goldman Sachs JBWere

Andrew JB Porter OAM

CFO / Company Secretary

Jan 2005

Regional COO, CSFB Corporate & Investment Banking; Andersen Consulting; Director of AUASB; former Chair of G100

Geoffrey N Driver

GM Business Development & Investor Relations

Jan 2003

18 years at National Australia Bank

Matthew J Rowe

Company Secretary

Jul 2016

Corporate governance adviser; UK funds-management company secretarial manager

Kieran Kennedy, CFA

Portfolio Manager (AICS investment team; listed by Yahoo Finance as AMCIL Portfolio Manager; presented at Mirrabooka FY2026 webcast)

——

“—” = not publicly disclosed.

Directors' Remuneration

Director (AUD)Fees FY2025Superannuation FY2025Total FY2025Fees FY2026Superannuation FY2026Total FY2026

R Myer (Chairman)

130,04514,955145,000129,46415,536145,000

R Brown

65,0227,47872,50064,7327,76872,500

P Dwyer

65,0227,47872,50072,500072,500

M Hirst

65,0227,47872,50064,7327,76872,500

J Webster

65,0227,47872,50064,7327,76872,500

J Auster (retired Oct 2024)

17,6692,04119,710———

R M Freeman (MD)

000000

Total

407,80246,908454,710396,16038,840435,000

Major Shareholders

RankHolderShares%
1

Teele Family Nominees Pty Ltd (Teele Family A/C)

20,914,5426.65
2

Mr Bruce Ballantine Teele

15,545,4874.94
3

Teele Family Foundation PL

15,191,4334.83
4

Djerriwarrh Investments Limited

11,235,6863.57
5

HSBC Custody Nominees (Australia)

5,949,7421.89
6

Invia Custodian (Christine Joy Campbell A/C)

4,996,2701.59
7

Invia Custodian (Terrence A Campbell A/C)

4,910,5421.56
8

Ancona Valley Holdings (Roswell Super Fund)

4,712,1151.50
9

R & J Webster (RJW Super Fund) — director-related

3,600,2601.14
10

Teele Family Super Pty Ltd

2,693,3370.86
11

Invia Custodian (Fobsha Pty Ltd A/C)

2,608,6930.83
12

Netwealth Investments (Wrap Services)

2,362,4390.75
13

Rogand Superannuation (Roger Brown-related)

2,260,0150.72
14

Citicorp Nominees

2,258,8420.72
15

BNP Paribas Noms (NZ)

2,110,0480.67
16

FFSF Asset Management (FF Super Fund)

2,050,0000.65
17

Chalcott Nominees (McGregor Family Super)

1,831,9450.58
18

Gardiole Pty Ltd (RH Myer Super Fund) — director-related

1,827,8970.58
19

Mrs Wai Ning Kenrick

1,813,0100.58
20

Mr Ross Ernest Barker

1,800,0000.57

Competitive Landscape

Key Competitors

CompetitorTypeRelative positioning vs AMCIL

Australian Foundation Investment Company (AFI)

Internally managed LIC (sister)

Same manager, diversified large-cap income focus, ~A$9.8bn portfolio, MER 0.14%; dominant scale

Argo Investments (ARG)

Internally managed LIC

~A$8.2bn total assets, MER 0.14%, 86 holdings, outperformed in FY2026; moving to quarterly dividends

Mirrabooka Investments (MIR)

Internally managed LIC (sister)

Mid/small-cap focus; A$635m portfolio; −10.8% FY2026 return; trades near NTA

Djerriwarrh Investments (DJW)

Internally managed LIC (sister)

Enhanced-income strategy using options; cross-holder of AMCIL

BKI Investment Company (BKI)

LIC

—

Australian United Investment Co (AUI)

LIC

—

Diversified United Investment (DUI)

LIC

—

WAM Leaders (WLE) / WAM Capital (WAM)

Externally managed LICs (Wilson Asset Management)

—

Whitefield Industrials (WHF)

LIC

—

Broad-market Australian equity ETFs (e.g., Vanguard VAS, iShares IOZ, Betashares A200)

Index ETFs

—

Peer Comparison FY2026

Metric (FY2026)AMCIL (AMH)AFIC (AFI)Argo (ARG)Mirrabooka (MIR)

Net profit (AUD Mn)

6.9293.5260.213.0

Portfolio size (AUD Mn)

339.39,800

not disclosed here (total assets 8200)

635.4

1-year portfolio return (%)

-10.00.98.7-10.8

Stated benchmark return (%)

7.27.26.17.8

MER (%)

0.570.140.14—

Pre-tax NTA per share (AUD)

1.087.9310.842.82

Total dividends declared (A$ cents)

4.031.538.5—

Share price vs NTA

-16.3% (30 Jun)

—

discount acknowledged, not quantified

-1.1% (24 Jul)

Company Snapshot

1996

Founded

Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Ungeared, liquid balance sheet: nil debt at every year-end FY2022–FY2026; A$10m undrawn CBA facility to 2028; 95% of assets are Level 1 listed securities (AR FY2026).
  • Low-cost, no-performance-fee model: MER 0.57% in FY2026 with administration costs down 9% year on year (A$2.111m vs A$2.314m) (AR FY2026).
  • Institutional-grade research platform: access to the AICS team servicing ~A$12bn across four LICs (AFIC announcement, 17 Feb 2026).
  • Distributable reserves for specials: realised capital gains reserve A$25.0m and franking capacity to frank ~A$12.0m of further dividends at 30 June 2026 (AR FY2026 Note A4).
  • Demonstrated upside capture in favourable regimes: FY2024 portfolio return of 20.5% vs 13.5% for the index (AR FY2024).
  • Aligned board and register: directors and executives hold ~10.7m shares; the former chairman's family controls ~17.3% (AR FY2026).

Weaknesses

  • Severe recent underperformance: −10.0% vs +7.2% in FY2026; 3-year 4.9% vs 11.9%; 5-year 2.3% vs 9.2%; 10-year 7.8% vs 10.9% p.a. (AR FY2026 Figure 3).
  • Persistent discount: 16.3% at 30 June 2026 vs 10% at 30 June 2023 (AR FY2024, AR FY2026).
  • Sub-scale cost structure: MER 0.57% vs 0.14% at AFIC and Argo (FY2026 results).
  • Declining income base: dividends received fell from A$9.37m (FY2023) to A$8.45m (FY2026) (AR FY2024, AR FY2026).
  • Ordinary dividend not covered by earnings: EPS 2.19c vs ordinary DPS 3.5c in FY2026 (AR FY2026).
  • Shrinking shareholder base: 3,350 holders (FY2022) to 2,876 (FY2026) (5-Year Summary).

Opportunities

  • Buy-back accretion: repurchasing at ~A$0.90 against NTA of ~A$1.08–1.09 is ~17–20% accretive per share bought (AR FY2026; NTA 2 Sep 2026).
  • Mean reversion in de-rated quality names: CSL, Cochlear, ResMed, CAR Group, SEEK, AUB were bought or held through drawdowns (AR FY2026).
  • Turnaround positions: Ramsay Health Care and ASX Ltd initiated after management changes (AR FY2026).
  • New-CEO reset: Gibson's arrival (13 Jul 2026) is a natural catalyst for strategy and discount-management review (AR FY2026).
  • Cash for dislocations: ~5% cash (A$16.9m) available to deploy (AR FY2026).
  • Higher deposit rates: interest income up 52% to A$818k in FY2026 (AR FY2026).

Threats

  • AI-disruption de-rating of software and classifieds materialised in FY2026 across WiseTech, REA, CAR Group, SEEK, Netwealth, Objective (AR FY2026).
  • Style regime risk: zero banks and underweight materials in a market led by resources (Materials +52.1%) (AR FY2026).
  • Tax policy risk to franking refunds or CGT treatment; LIC capital-gain mechanism depends on tax legislation (AR FY2026 LIC Capital Gains section).
  • Activist or corporate-action pressure given the persistent discount and a concentrated register (inference; no activist activity identified).
  • Key-person and transition risk following the departure of a 31-year veteran (AR FY2026 Board Changes).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 May 2025Investor presentation released TradingView documents listMarketing to address discount
Weekly, ongoingEstimated pre-tax NTA published weekly AR FY2026Transparency initiative
31 Jul 2025FY2025 results: profit A$6.7m (from A$7.5m); 2.5c final + 3.0c special; portfolio return 6.4% vs index 15.1%; MER 0.56% FNN FY2025Second year of underperformance begins; large special from bank/Wesfarmers/CBA realised gains
Aug 2025Teele substantial holding at 54.34m shares (17.28%) recorded by MarketScreenerConcentrated register
8 Aug 2025Ex-date for 5.5c final + special InvestSMART—
27 Aug 20255.5c paid (A$17.1m); DRP issue 5.41m shares at A$1.11 AR FY2026Large DRP take-up
27 Aug 2025FY2025 Annual Report and AGM documents lodged ASXStatutory
1 Oct 20252025 AGM, RACV Club Melbourne (hybrid); ASA monitor report records ~A$340m market capitalisation ASA 2025 AGM reportGovernance
Jul 2025 – Jun 2026On-market buy-back of 7.53m shares for A$7.6m AR FY2026Capital management at discount
H1 FY2026Exits of Westpac and NAB on valuation; banks to zero AR FY2026Positioning; later proved the largest positive relative contributor (not holding CBA)
22 Jan 2026H1 FY2026: profit A$4.1m (+14.8%) on options income; 6-month portfolio return −7.0% vs index +4.2%; NTA A$1.12; total comprehensive income −A$19.9m; interim 1.0c Half-Year ReportUnderperformance accelerates
22 Jan 2026On-market buy-back plan announced InvestSMART logDiscount response
2 Feb 2026Ex-date interim 1.0c Market Index—
17 Feb 2026Mark Freeman retirement announced; Alison Gibson appointed successor across AFIC, DJW, MIR, AMH and AICS AFIC/AMCIL announcementsLeadership transition; AFIC-group FUM grew from ~A$1bn to ~A$12bn under Freeman's involvement
24 Feb 2026Interim dividend paid (A$3.1m); DRP 0.95m shares at A$1.00 AR FY2026—
11 Mar 2026Substantial-holder notice date for Bruce Teele (54.34m shares) per AR FY2026Register
H2 FY2026Exits of REA, WiseTech, EQT, ReadyTech, Beamtree, Redox, Environmental Group, IDP Education; new Ramsay, ASX, AUB, Nanosonics AR FY2026Portfolio restructuring; fewer holdings
30 Jun 2026Freeman retires; FY2026 portfolio return −10.0% vs +7.2% AR FY2026Worst relative year in the period
13 Jul 2026Estimated NTA A$1.07 at 10 Jul; share price A$0.92 ASX NTA release~14% discount
13 Jul 2026Alison Gibson commences as MD & CEO; initial director's interest notice (no AMH shares) AR FY2026; Market IndexNew leadership
20 Jul 2026Estimated NTA A$1.07 (17 Jul); price A$0.93 Kalkine (NTA release)—
27 Jul 2026Estimated NTA A$1.04 (24 Jul); price A$0.94 ASX NTA release—
28 Jul 2026FY2026 results: profit A$6.92m (+3.6%); 2.5c final + 0.5c special; NTA A$1.08; discount 16.3%; MER 0.57%; webcast held Appendix 4E; webcastResults
7–10 Aug 2026Ex-date (7 Aug) and record date (10 Aug) for 3.0c Dividend notice—
24 Aug 2026Estimated NTA A$1.08 ex-dividend (21 Aug); price A$0.90 ASX NTA releaseDiscount ~17%
31 Aug 20263.0c paid (~A$9.4m); FY2026 Annual Report and Notice of AGM lodged ASXStatutory
2 Sep 2026August NTA: A$1.09 pre-tax / A$0.99 post-tax (ex-div); portfolio A$342.2m Monthly NTAModest recovery post year-end
1 Oct 20262026 AGM held (hybrid, ZINC Federation Square); results of meeting lodged 3:12pm AEST Market Index logFirst AGM under Gibson

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Total revenue — dividends, interest, other fell from AUD 9.8 Mn in FY2023 to AUD 9.3 Mn in FY2026.
Amcil Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2023FY2024FY2025FY2026
Total revenue — dividends, interest, other9.89.59.19.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. AMCIL Limited, Statutory Annual Report and Annual Shareholder Review 2026 (lodged 31 Aug 2026) (bulletin.webull.com)
  2. AMCIL Limited, Annual Report 2024 (lodged 27 Aug 2024) (announcements.asx.com.au)
  3. AMCIL Limited, Annual Report 2025 (lodged 27 Aug 2025) (announcements.asx.com.au)
  4. AMCIL Limited, Annual Report 2023 (lodged 23 Aug 2023) (announcements.asx.com.au)
  5. AMCIL FY2026 Results for Announcement to the Market (28 Jul 2026) (investorpa.com)
  6. AMCIL FY2026 Results Webcast Presentation (28 Jul 2026) (bulletin.webull.com)
  7. AMCIL Monthly NTA and Top 20 at 31 Aug 2026 (bulletin.webull.com)
  8. AMCIL weekly NTA releases (10 Jul, 24 Jul, 21 Aug 2026) · bulletin.webull.com · bulletin.webull.com
  9. AMCIL Notice of AGM 2026 (announcements.asx.com.au)
  10. AMCIL Results of 2026 AGM (announcement listing) (marketindex.com.au)
  11. InvestSMART announcement summaries (FY2026 results; H1 FY2026; CEO retirement; H1 FY2025) · investsmart.com.au · investsmart.com.au · investsmart.com.au
  12. InvestSMART AMH financials and quote pages · investsmart.com.au
  13. AFIC leadership announcement (17 Feb 2026) (announcements.nzx.com)
  14. Finance News Network — AMCIL FY2025 and FY2024 results interviews · finnewsnetwork.com.au
  15. Quartr — AMCIL H2 2026 earnings summary (quartr.com)
  16. FilingReader — AMCIL FY2026 results summaries · filingreader.com
  17. Market Index — AMH profile, dividends, director trades; Alison Gibson profile · marketindex.com.au
  18. TradingView — AMH profile (founding/IPO dates, ISIN) (tradingview.com)
  19. Stoxray — AMH historical revenue, net income, CFO (stoxray.com)
  20. MarketScreener — Bruce Teele holdings (marketscreener.com)
  21. Yahoo Finance — AMH profile (au.finance.yahoo.com)
  22. Australian Shareholders' Association AGM reports (2020, 2021, 2024, 2025) · australianshareholders.com.au · australianshareholders.com.au · australianshareholders.com.au
  23. AFIC FY2026 results · fool.com.au · filingreader.com
  24. Argo Investments FY2026 results · filingreader.com
  25. Mirrabooka Investments FY2026 results and NTA · kalkinemedia.com · kalkinemedia.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.